Scientists from Roman Catholic University have explored modifications to the LIMK1 protein with the aim of enhancing memory function. The findings were reported in the journal Science Developments.
The LIMK1 protein is known to contribute to the formation of dendritic spines, tiny protrusions on nerve cells that are critical for synaptic connections, learning, and memory. In this study, researchers genetically engineered the LIMK1 molecule in mice by introducing a molecular switch within its structure. This switch could be activated by the drug rapamycin, an agent with immunosuppressive properties that has previously been associated with extended lifespan in animals and with cognitive improvements in certain models (Attribution: Science Developments).
In aged mice or models of cognitive decline, the team combined gene therapy to replace LIMK1 with an activated form that responds to rapamycin. The result was notable improvements in memory tasks and learning ability, offering a potential pathway toward treating brain disorders through engineered proteins. The researchers stress that while hope is growing, these results are early and primarily in animal models (Attribution: Science Developments).
Looking ahead, the next phase involves testing the treatment in experimental models of neurodegenerative diseases that exhibit memory deficits, such as Alzheimer’s disease. The authors emphasize the need for additional research to assess safety, dosage, and efficacy before any application in humans can be considered (Attribution: Science Developments).
In related work, investigators have examined how certain pharmacological strategies may influence cardiovascular risk and weight management, underscoring the broader interest in how molecular and genetic approaches could support healthspan and cognitive function (Attribution: Science Developments).